Why Aurora Cannabis (TSX:ACB) Stock Fell 16% Over the Past Week

Aurora Cannabis Inc. (TSX:ACB)(NYSE:ACB) stock surged in May, but investors have once again soured on the company as the weather has turned.

| More on:
edit Jars of marijuana

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

The cannabis sector has been interesting to watch during the COVID-19 pandemic. In early April, I’d asked whether the fledgling industry was recession proof. Cannabis sales spiked in March as consumers stocked up on reserves, and we have since witnessed periodic spikes in activity.

Overall, cannabis has shown resilience like other sin stocks. Aurora Cannabis (TSX:ACB)(NYSE:ACB), one of the top producers in Canada, managed to stage a rally in May.

Unfortunately, this momentum has stalled. Shares of Aurora have dropped 16% week over week. Let’s explore why this has occurred.

Aurora Cannabis: A bump after earnings and an acquisition

Aurora stock rose on the back of two developments in recent weeks. The company released its third quarter fiscal 2020 results on May 14. Consumer cannabis net revenue increased 24% year over year to $41.5 million.

Management underwent an operational reset after the departure of CEO Terry Booth earlier this year. Aurora is now on track to achieved profitability by the first quarter of fiscal 2021.

About a week after this solid earnings report, Aurora Cannabis received another boost. It agreed to buy U.S.-based company Reliva, granting Aurora a foothold south of the border. This move also grants Aurora access to the burgeoning cannabinoid market. However, some analysts are not entirely convinced of its efficacy in the long term. The acquisition was completed on May 28.

Investors are still skeptical

Investors in Aurora have seen their shares diluted on several occasions. The $40 million price tag for Reliva forced Aurora to issue 2.5 million new shares. If its valuation continues to sink in the coming weeks, Aurora could be forced to issues several million more shares to pay the additional $45 million contingent fee for Reliva.

On the other hand, investors have reasons to be optimistic. Aurora Cannabis opted for dilution rather than dip into its cash reserves. The company has bled a lot of cash over the past year, and investors had just started to see improvement in the most recent quarter.

As it stands today, Aurora boasts a very good balance sheet as we look ahead to the final quarter of fiscal 2020.

Should you have faith in Aurora today?

Shares of Aurora last had a favourable price-to-book value of 0.5. The stock last had an RSI of 58, putting it closer to technically overbought territory at the time of this writing. While cannabis sales have shown some signs of improvement in the spring, the increase has not been substantial enough to spark a huge turn in fortunes.

Many consumers are still turning to the black market. Ontario aimed to expand its brick-and-mortar retail footprint in 2020, but the COVID-19 pandemic has put a dent in these plans.

Aurora Cannabis deserves praise for improving its cash position. However, the middling state of Canada’s domestic market may continue to hold it and other top producers back going forward.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ambrose O'Callaghan has no position in any of the stocks mentioned.

More on Cannabis Stocks

IMAGE OF A NOTEBOOK WITH TFSA WRITTEN ON IT
Cannabis Stocks

TFSA Investors: 2 U.S. Stocks I’m Never Selling

Canadians looking to diversify their portfolios and gain exposure to U.S. stocks can purchase shares of high-growth companies such as…

Read more »

A cannabis plant grows.
Cannabis Stocks

Aurora Cannabis (TSX:ACB) Keeps Burning Cash as Revenue Falls

Aurora Cannabis (TSX:ACB)(NASDAQ:ACB) is still losing money. Its revenue is declining, too.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

Why Canopy Growth Stock Climbed as Much as 20% on Monday

A glimmer of hope from the U.S. Congress may lead to renewed interest in marijuana investing.

Read more »

TSX Today
Cannabis Stocks

TSX Today: What to Watch for in Stocks on Friday, July 15

A continued selloff in metals prices is likely to pressure the commodity-heavy TSX Composite benchmark at the open today.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

With the Cannabis Industry Trading Ultra-Cheap, Organigram Stock Looks Like a Screaming Buy!

After selling off for years, Organigram stock now offers tonnes of value and is easily one of the best cannabis…

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Canopy Growth Stock: The Only Cannabis Stock to Consider Long Term

The cannabis stock industry remains an incredibly high risk one, but Canopy Growth (TSX:WEED)(NYSE:CGC) stock provides the best opportunity for…

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Should You Stay Away From HEXO Stock?

HEXO (TSX:HEXO)(NASDAQ:HEXO) stock is on a downward spiral, and there is little hope it is going to recover soon.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why Did Aurora Cannabis (TSX:ACB) Stock Plunge 75% in 2022?

A prominent cannabis stock has plunged by 75% in 2022, as the company’s losses continue to mount in the face…

Read more »